Shenzhen Antiv Pharma

Antiv Pharma is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, dedicated to the discovery and development of innovative small molecule drugs for infectious diseases. The company's primary focus is on respiratory viral pathogens, including influenza, SARS-CoV-2, and respiratory syncytial virus (RSV). Its lead product candidate, Onradivir (ADC189), is a highly potent cap-dependent endonuclease inhibitor that has completed Phase 3 clinical trials for the treatment of uncomplicated influenza. Antiv Pharma aims to address significant unmet medical needs by developing oral therapies with superior efficacy and safety profiles compared to current standards of care. The company is supported by a robust investor base, including GL Ventures and Legend Capital, and maintains a strong R&D presence in the Guangdong-Hong Kong-Macao Greater Bay Area.